{"id":"https://openalex.org/W3177941998","doi":"https://doi.org/10.1158/1535-7163.mct-21-0035","title":"Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo","display_name":"Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo","alternate_titles":[],"publication_year":2021,"publication_date":"2021-07-12","ids":{"openalex":"https://openalex.org/W3177941998","doi":"https://doi.org/10.1158/1535-7163.mct-21-0035","mag":"3177941998","pmid":"https://pubmed.ncbi.nlm.nih.gov/34253590","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9398105"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-21-0035","doi":"https://doi.org/10.1158/1535-7163.mct-21-0035","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-21-0035","pdf_url":"https://aacrjournals.org/mct/article-pdf/20/10/1941/3198522/1941.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3177941998"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://aacrjournals.org/mct/article-pdf/20/10/1941/3198522/1941.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058384217","display_name":"Rocio Montes De Oca","orcid":"https://orcid.org/0000-0002-6576-7240","observed_orcids":["https://orcid.org/0000-0002-6576-7240"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/data-curation","display_name":"Data curation"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/project-administration","display_name":"Project administration"},{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"},{"id":"https://openalex.org/contributor-roles/validation","display_name":"Validation"},{"id":"https://openalex.org/contributor-roles/visualization","display_name":"Visualization"},{"id":"https://openalex.org/contributor-roles/writing-original-draft","display_name":"Writing \u2013 original draft"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Rocio Montes de Oca","raw_affiliation_strings":["1Experimental Medicine Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":"https://orcid.org/0000-0002-6576-7240","affiliations":[{"raw_affiliation_string":"1Experimental Medicine Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081406457","display_name":"Alireza Alavi","orcid":"https://orcid.org/0000-0002-5502-2616","observed_orcids":["https://orcid.org/0000-0002-5502-2616"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/data-curation","display_name":"Data curation"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"},{"id":"https://openalex.org/contributor-roles/visualization","display_name":"Visualization"},{"id":"https://openalex.org/contributor-roles/writing-original-draft","display_name":"Writing \u2013 original draft"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Alireza S. Alavi","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":"https://orcid.org/0000-0002-5502-2616","affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009598034","display_name":"Nick Vitali","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Nick Vitali","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sabyasachi Bhattacharya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Sabyasachi Bhattacharya","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039345673","display_name":"Christina Blackwell","orcid":"https://orcid.org/0009-0000-5585-3658","observed_orcids":["https://orcid.org/0009-0000-5585-3658"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Christina Blackwell","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102143832","display_name":"Krupa J. Patel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Krupa Patel","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000219610","display_name":"Laura Seestaller\u2010Wehr","orcid":"https://orcid.org/0009-0004-4149-5203","observed_orcids":["https://orcid.org/0009-0004-4149-5203"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Laura Seestaller-Wehr","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074622859","display_name":"Heather Kaczynski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Heather Kaczynski","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100523117","display_name":"Hong Shi","orcid":"https://orcid.org/0000-0002-9642-2317","observed_orcids":["https://orcid.org/0000-0002-9642-2317"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Hong Shi","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027493388","display_name":"Eric Dobrzynski","orcid":"https://orcid.org/0000-0001-5944-2178","observed_orcids":["https://orcid.org/0000-0001-5944-2178"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Eric Dobrzynski","raw_affiliation_strings":["3Bioanalysis, Immunogenicity and Biomarkers, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Bioanalysis, Immunogenicity and Biomarkers, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013776234","display_name":"Leslie Obert","orcid":"https://orcid.org/0000-0001-9788-2908","observed_orcids":["https://orcid.org/0000-0001-9788-2908"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"}],"raw_author_name":"Leslie Obert","raw_affiliation_strings":["4Translational Medicine and Comparative Pathobiology, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":"https://orcid.org/0000-0001-9788-2908","affiliations":[{"raw_affiliation_string":"4Translational Medicine and Comparative Pathobiology, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044999604","display_name":"Lyuben M. Tsvetkov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"}],"raw_author_name":"Lyuben Tsvetkov","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110944599","display_name":"David C. Cooper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"David C. Cooper","raw_affiliation_strings":["5Research Statistics, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Research Statistics, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002480924","display_name":"Heather L. Jackson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Heather Jackson","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072054295","display_name":"Paul M. Bojczuk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Paul Bojczuk","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024146713","display_name":"Sabrina Forveille","orcid":"https://orcid.org/0000-0002-9327-470X","observed_orcids":["https://orcid.org/0000-0002-9327-470X"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I204730241","display_name":"Universit\u00e9 Paris Cit\u00e9","ror":"https://ror.org/05f82e368","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241"]},{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I39804081","display_name":"Sorbonne Universit\u00e9","ror":"https://ror.org/02en5vm52","country_code":"FR","type":"education","lineage":["https://openalex.org/I39804081"]},{"id":"https://openalex.org/I4210092322","display_name":"Centre de Recherche des Cordeliers","ror":"https://ror.org/00dmms154","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Sabrina Forveille","raw_affiliation_strings":["6Equipe labellis\u00e9e par la Ligue contre le cancer, Universit\u00e9 de Paris, Sorbonne Universit\u00e9, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France","7Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Equipe labellis\u00e9e par la Ligue contre le cancer, Universit\u00e9 de Paris, Sorbonne Universit\u00e9, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]},{"raw_affiliation_string":"7Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056768522","display_name":"Oliver Kepp","orcid":"https://orcid.org/0000-0002-6081-9558","observed_orcids":["https://orcid.org/0000-0002-6081-9558"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I204730241","display_name":"Universit\u00e9 Paris Cit\u00e9","ror":"https://ror.org/05f82e368","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241"]},{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I39804081","display_name":"Sorbonne Universit\u00e9","ror":"https://ror.org/02en5vm52","country_code":"FR","type":"education","lineage":["https://openalex.org/I39804081"]},{"id":"https://openalex.org/I4210092322","display_name":"Centre de Recherche des Cordeliers","ror":"https://ror.org/00dmms154","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Oliver Kepp","raw_affiliation_strings":["6Equipe labellis\u00e9e par la Ligue contre le cancer, Universit\u00e9 de Paris, Sorbonne Universit\u00e9, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France","7Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France"],"raw_orcid":"https://orcid.org/0000-0002-6081-9558","affiliations":[{"raw_affiliation_string":"6Equipe labellis\u00e9e par la Ligue contre le cancer, Universit\u00e9 de Paris, Sorbonne Universit\u00e9, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]},{"raw_affiliation_string":"7Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016175389","display_name":"Allan Sauvat","orcid":"https://orcid.org/0000-0001-7076-8638","observed_orcids":["https://orcid.org/0000-0001-7076-8638"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I204730241","display_name":"Universit\u00e9 Paris Cit\u00e9","ror":"https://ror.org/05f82e368","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241"]},{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I39804081","display_name":"Sorbonne Universit\u00e9","ror":"https://ror.org/02en5vm52","country_code":"FR","type":"education","lineage":["https://openalex.org/I39804081"]},{"id":"https://openalex.org/I4210092322","display_name":"Centre de Recherche des Cordeliers","ror":"https://ror.org/00dmms154","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Allan Sauvat","raw_affiliation_strings":["6Equipe labellis\u00e9e par la Ligue contre le cancer, Universit\u00e9 de Paris, Sorbonne Universit\u00e9, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France","7Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Equipe labellis\u00e9e par la Ligue contre le cancer, Universit\u00e9 de Paris, Sorbonne Universit\u00e9, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]},{"raw_affiliation_string":"7Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075296559","display_name":"Guido Kroemer","orcid":"https://orcid.org/0000-0002-9334-4405","observed_orcids":["https://orcid.org/0000-0002-9334-4405"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I200296433","display_name":"Chinese Academy of Medical Sciences & Peking Union Medical College","ror":"https://ror.org/02drdmm93","country_code":"CN","type":"education","lineage":["https://openalex.org/I200296433"]},{"id":"https://openalex.org/I204730241","display_name":"Universit\u00e9 Paris Cit\u00e9","ror":"https://ror.org/05f82e368","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241"]},{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I39804081","display_name":"Sorbonne Universit\u00e9","ror":"https://ror.org/02en5vm52","country_code":"FR","type":"education","lineage":["https://openalex.org/I39804081"]},{"id":"https://openalex.org/I4210092322","display_name":"Centre de Recherche des Cordeliers","ror":"https://ror.org/00dmms154","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210102325","display_name":"H\u00f4pital Europ\u00e9en Georges-Pompidou","ror":"https://ror.org/016vx5156","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210102325","https://openalex.org/I4210120235"]}],"countries":["CN","FR","SE"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/funding-acquisition","display_name":"Funding acquisition"},{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Guido Kroemer","raw_affiliation_strings":["10Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden","6Equipe labellis\u00e9e par la Ligue contre le cancer, Universit\u00e9 de Paris, Sorbonne Universit\u00e9, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France","7Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France","8P\u00f4le de Biologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Paris, France","9Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, P.R. China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden","institution_ids":["https://openalex.org/I1335113835","https://openalex.org/I28166907"]},{"raw_affiliation_string":"6Equipe labellis\u00e9e par la Ligue contre le cancer, Universit\u00e9 de Paris, Sorbonne Universit\u00e9, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]},{"raw_affiliation_string":"7Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]},{"raw_affiliation_string":"8P\u00f4le de Biologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Paris, France","institution_ids":["https://openalex.org/I4210097159","https://openalex.org/I4210102325"]},{"raw_affiliation_string":"9Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, P.R. China","institution_ids":["https://openalex.org/I200296433"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090847503","display_name":"Mark Creighton-Gutteridge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Mark Creighton-Gutteridge","raw_affiliation_strings":["11Cell Therapy RU, Oncology R&D, GlaxoSmithKline, Hertfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Cell Therapy RU, Oncology R&D, GlaxoSmithKline, Hertfordshire, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113656936","display_name":"Jingsong Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"}],"raw_author_name":"Jingsong Yang","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051838654","display_name":"Chris Hopson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"}],"raw_author_name":"Chris Hopson","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059937355","display_name":"Niranjan Yanamandra","orcid":"https://orcid.org/0009-0002-1585-6007","observed_orcids":["https://orcid.org/0009-0002-1585-6007"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"}],"raw_author_name":"Niranjan Yanamandra","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113872669","display_name":"Christopher A. Shelton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Christopher Shelton","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046901107","display_name":"Patrick A. Mayes","orcid":"https://orcid.org/0000-0001-9104-4161","observed_orcids":["https://orcid.org/0000-0001-9104-4161"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"}],"raw_author_name":"Patrick Mayes","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023624767","display_name":"Joanna Opalinska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/funding-acquisition","display_name":"Funding acquisition"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Joanna Opalinska","raw_affiliation_strings":["12Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051901418","display_name":"Mary S. Barnette","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/funding-acquisition","display_name":"Funding acquisition"},{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"}],"raw_author_name":"Mary Barnette","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062921585","display_name":"Roopa Srinivasan","orcid":"https://orcid.org/0009-0005-9090-2394","observed_orcids":["https://orcid.org/0009-0005-9090-2394"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/funding-acquisition","display_name":"Funding acquisition"},{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"}],"raw_author_name":"Roopa Srinivasan","raw_affiliation_strings":["1Experimental Medicine Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental Medicine Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045119909","display_name":"James F . Smothers","orcid":"https://orcid.org/0000-0002-7627-3051","observed_orcids":["https://orcid.org/0000-0002-7627-3051"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/funding-acquisition","display_name":"Funding acquisition"},{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"}],"raw_author_name":"James Smothers","raw_affiliation_strings":["2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086481435","display_name":"Axel Hoos","orcid":"https://orcid.org/0000-0001-5269-9376","observed_orcids":["https://orcid.org/0000-0001-5269-9376"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/funding-acquisition","display_name":"Funding acquisition"},{"id":"https://openalex.org/contributor-roles/resources","display_name":"Resources"}],"raw_author_name":"Axel Hoos","raw_affiliation_strings":["12Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":12,"corresponding_author_ids":["https://openalex.org/A5058384217"],"corresponding_institution_ids":["https://openalex.org/I4210114143"],"apc_list":null,"apc_paid":null,"fwci":6.2872,"has_fulltext":true,"cited_by_count":133,"citation_normalized_percentile":{"value":0.97908,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":100},"biblio":{"volume":"20","issue":"10","first_page":"1941","last_page":"1955"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.5264000296592712,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.5264000296592712,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.3668999969959259,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.04569999873638153,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/belantamab-mafodotin","display_name":"belantamab mafodotin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.7179999947547913},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9229999780654907},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9369999766349792},{"id":"https://openalex.org/keywords/immunogenic-cell-death","display_name":"immunogenic cell death","score":0.9860000014305115},{"id":"https://openalex.org/keywords/dendritic-cell-activation","display_name":"dendritic cell activation","score":0.9819999933242798},{"id":"https://openalex.org/keywords/tumor-immune-infiltration","display_name":"tumor immune infiltration","score":0.6660000085830688},{"id":"https://openalex.org/keywords/adaptive-immune-response","display_name":"adaptive immune response","score":0.6309999823570251},{"id":"https://openalex.org/keywords/immunological-memory","display_name":"immunological memory","score":0.9110000133514404},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.8759999871253967},{"id":"https://openalex.org/keywords/el4-lymphoma","display_name":"EL4 lymphoma","score":0.7419999837875366},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.8399999737739563}],"concepts":[{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.765924870967865},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5458928942680359},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5370027422904968},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5325298309326172},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5299478769302368},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.5113934874534607},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.47496411204338074},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.46596813201904297},{"id":"https://openalex.org/C2777877232","wikidata":"https://www.wikidata.org/wiki/Q17144704","display_name":"Immunogenic cell death","level":4,"score":0.4450320303440094},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.43916380405426025},{"id":"https://openalex.org/C193419808","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired immune system","level":3,"score":0.42628568410873413},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.42058542370796204},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4071978032588959},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.21048644185066223},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000079527","descriptor_name":"Immunogenic Cell Death","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008223","descriptor_name":"Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008223","descriptor_name":"Lymphoma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008223","descriptor_name":"Lymphoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008223","descriptor_name":"Lymphoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008810","descriptor_name":"Mice, Inbred C57BL","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018414","descriptor_name":"CD8-Positive T-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053301","descriptor_name":"B-Cell Maturation Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D053301","descriptor_name":"B-Cell Maturation Antigen","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1158/1535-7163.mct-21-0035","doi":"https://doi.org/10.1158/1535-7163.mct-21-0035","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-21-0035","pdf_url":"https://aacrjournals.org/mct/article-pdf/20/10/1941/3198522/1941.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9398105","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9398105/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"},{"id":"pmid:34253590","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34253590","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:HAL:hal-03568613v1","doi":null,"is_oa":true,"landing_page_url":"https://hal.sorbonne-universite.fr/hal-03568613","pdf_url":"https://hal.sorbonne-universite.fr/hal-03568613v1/file/1941.full.pdf","source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics, 2021, 20 (10), pp.1941 - 1955. &#x27E8;10.1158/1535-7163.mct-21-0035&#x27E9;","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.mct-21-0035","doi":"https://doi.org/10.1158/1535-7163.mct-21-0035","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-21-0035","pdf_url":"https://aacrjournals.org/mct/article-pdf/20/10/1941/3198522/1941.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320308590","display_name":"University of California","ror":"https://ror.org/00pjdza24"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3177941998.pdf","grobid_xml":"https://content.openalex.org/works/W3177941998.grobid-xml"},"referenced_works_count":50,"referenced_works":["https://openalex.org/W1504403518","https://openalex.org/W1611944043","https://openalex.org/W1651563658","https://openalex.org/W1942897646","https://openalex.org/W1981654979","https://openalex.org/W1982877913","https://openalex.org/W1998074965","https://openalex.org/W1999998145","https://openalex.org/W2005150159","https://openalex.org/W2010844627","https://openalex.org/W2015095309","https://openalex.org/W2016612145","https://openalex.org/W2023980114","https://openalex.org/W2025111868","https://openalex.org/W2029765161","https://openalex.org/W2046290067","https://openalex.org/W2047521557","https://openalex.org/W2062254683","https://openalex.org/W2071055446","https://openalex.org/W2081796577","https://openalex.org/W2084623259","https://openalex.org/W2088324610","https://openalex.org/W2093424661","https://openalex.org/W2096365030","https://openalex.org/W2100106580","https://openalex.org/W2107598346","https://openalex.org/W2120426523","https://openalex.org/W2130153302","https://openalex.org/W2141285069","https://openalex.org/W2156253561","https://openalex.org/W2158500407","https://openalex.org/W2163621501","https://openalex.org/W2165559987","https://openalex.org/W2171942860","https://openalex.org/W2172268423","https://openalex.org/W2173303337","https://openalex.org/W2184270030","https://openalex.org/W2252550602","https://openalex.org/W2296047035","https://openalex.org/W2422962677","https://openalex.org/W2556735910","https://openalex.org/W2592467398","https://openalex.org/W2798140657","https://openalex.org/W2901760736","https://openalex.org/W2923666301","https://openalex.org/W2940945106","https://openalex.org/W2970536272","https://openalex.org/W2995934717","https://openalex.org/W3021927596","https://openalex.org/W3044244229"],"related_works":["https://openalex.org/W2952039293","https://openalex.org/W7214711748","https://openalex.org/W1982877913","https://openalex.org/W2984661502","https://openalex.org/W3087735636","https://openalex.org/W4313312719","https://openalex.org/W3082666946","https://openalex.org/W2796115040","https://openalex.org/W4376106006","https://openalex.org/W4413796318"],"abstract_inverted_index":{"B-cell":[0,20],"maturation":[1],"antigen":[2,112],"(BCMA)":[3],"is":[4,26],"an":[5,104,127],"attractive":[6],"therapeutic":[7],"target":[8],"highly":[9],"expressed":[10],"on":[11],"differentiated":[12],"plasma":[13],"cells":[14,50],"in":[15,47,56,59,78],"multiple":[16,37],"myeloma":[17],"and":[18,51,58,68,73,98,110,135],"other":[19],"malignancies.":[21],"GSK2857916":[22,42,61,148],"(belantamab":[23],"mafodotin,":[24],"BLENREP)":[25],"a":[27,141],"BCMA-targeting":[28],"antibody\u2013drug":[29],"conjugate":[30],"approved":[31],"for":[32,144],"the":[33],"treatment":[34,62],"of":[35,103,119,147],"relapsed/refractory":[36],"myeloma.":[38],"We":[39],"report":[40],"that":[41],"induces":[43],"immunogenic":[44],"cell":[45,54,66],"death":[46],"BCMA-expressing":[48],"cancer":[49],"promotes":[52,74],"dendritic":[53],"activation":[55],"vitro":[57],"vivo.":[60],"enhances":[63],"intratumor":[64],"immune":[65,92,106,128,154],"infiltration":[67],"activation,":[69],"delays":[70],"tumor":[71,111],"growth,":[72],"durable":[75,137],"complete":[76,138],"regressions":[77],"immune-competent":[79],"mice":[80,90],"bearing":[81],"EL4":[82,96],"lymphoma":[83],"tumors":[84],"expressing":[85],"human":[86],"BCMA":[87],"(EL4-hBCMA).":[88],"Responding":[89],"are":[91,115],"to":[93],"rechallenge":[94],"with":[95,125,150],"parental":[97],"EL4-hBCMA":[99],"cells,":[100],"suggesting":[101],"engagement":[102],"adaptive":[105,153],"response,":[107],"immunologic":[108],"memory,":[109],"spreading,":[113],"which":[114],"abrogated":[116],"upon":[117],"depletion":[118],"endogenous":[120],"CD8+":[121],"T":[122],"cells.":[123],"Combinations":[124],"OX40/OX86,":[126],"agonist":[129],"antibody,":[130],"significantly":[131],"enhance":[132],"antitumor":[133],"activity":[134],"increase":[136],"responses,":[139,155],"providing":[140],"strong":[142],"rationale":[143],"clinical":[145],"evaluation":[146],"combinations":[149],"immunotherapies":[151],"targeting":[152],"including":[156],"T-cell\u2013directed":[157],"checkpoint":[158],"modulators.":[159]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3177941998","counts_by_year":[{"year":2026,"cited_by_count":36},{"year":2025,"cited_by_count":22},{"year":2024,"cited_by_count":30},{"year":2023,"cited_by_count":25},{"year":2022,"cited_by_count":19},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2021-07-19T00:00:00"}
